In partnership with
Onychomycosis: No advantage of pulse therapy versus continuous treatment
New analysis of ECLIPSE trial: skin clearance independent of PsA status at baseline
JAK inhibitor leads to rapid improvement of AD of head and neck
Depression increases the risk of psoriasis
Intranasal butorphanol: a successful rescue therapy for intractable pruritus
Spironolactone safe in breast cancer survivors
Novel IL-23 blocker highly effective in psoriasis over a year
IL-4/IL-13 blockade effective in children with severe AD
Abrocitinib – a selective JAK1 inhibitor successful in AD treatment
Tape-stripping: a new mode of disease distinction without biopsy?
Emollient in stick format improves compliance in AD skin care
Advanced melanoma – baseline characteristics can predict disease control and toxicity
Novel AD biologic on the horizon
Biologics for treatment of psoriasis in cancer patients – a complex relationship
Local glycopyrronium bromide effective in primary hyperhidrosis
Omalizumab – suitable treatment for cancer induced dermatoses?
Selective IL-23 blocker effective and tolerable in elderly patients
Increased risk of SLE in hidradenitis suppurativa patients
Top image: © damiangretka
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
BACK TO TOP